Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2026 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...
May 12, 2026 07:00 ET | Source: https://immatics.com/

Immatics Announces First Quarter 2026 Financial Results and Business Update

SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027Multiple key...
May 08, 2026 16:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies...
May 07, 2026 09:34 ET | Source: Research and Markets

Unituxin (United Therapeutics) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Unituxin Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
May 07, 2026 09:19 ET | Source: Research and Markets

Elzonris (Menarini Group) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Elzonris Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
May 07, 2026 06:00 ET | Source: LIfT BioSciences

LIfT Biosciences Establishes Scientific Advisory Board to Accelerate Development of Neutrophil-based Cancer Therapies

Members include Nobel laureate James P. Allison, Padmanee Sharma, Taha Merghoub, and Kingston Mills, who are all globally renowned experts in cancer immunotherapy and translational cancer...
May 04, 2026 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Conference Call Scheduled for Friday, May 15, 2026, at 1:00 PM ET NEEDHAM, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage...
May 01, 2026 16:05 ET | Source: Candel Therapeutics

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
April 30, 2026 07:00 ET | Source: AC Immune SA

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12...
April 28, 2026 08:30 ET | Source: Enlivex Ltd.

Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million

New acquisitions from Rain Foundation underlines Enlivex’s disciplined prediction markets treasury strategy Nes-Ziona, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV,...